BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27622335)

  • 1. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
    Zeng H; Qu J; Jin N; Xu J; Lin C; Chen Y; Yang X; He X; Tang S; Lan X; Yang X; Chen Z; Huang M; Ding J; Geng M
    Cancer Cell; 2016 Sep; 30(3):459-473. PubMed ID: 27622335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
    Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
    Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.
    Huang Z; Zhou W; Li Y; Cao M; Wang T; Ma Y; Guo Q; Wang X; Zhang C; Zhang C; Shen W; Liu Y; Chen Y; Zheng J; Yang S; Fan Y; Xiang R
    Theranostics; 2018; 8(18):4995-5011. PubMed ID: 30429882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Novel Pyrrolo[2,3-
    Liang X; Tang S; Liu X; Liu Y; Xu Q; Wang X; Saidahmatov A; Li C; Wang J; Zhou Y; Zhang Y; Geng M; Huang M; Liu H
    J Med Chem; 2022 Jan; 65(2):1243-1264. PubMed ID: 33586434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer.
    Zhao C; Zhang Y; Zhang J; Li S; Liu M; Geng Y; Liu F; Chai Q; Meng H; Li M; Li J; Zheng Y; Zhang Y
    J Med Chem; 2023 Oct; 66(20):14150-14174. PubMed ID: 37796543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
    Amemiya S; Yamaguchi T; Hashimoto Y; Noguchi-Yachide T
    Bioorg Med Chem; 2017 Jul; 25(14):3677-3684. PubMed ID: 28549889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
    Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
    Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
    Borbely G; Haldosen LA; Dahlman-Wright K; Zhao C
    Oncotarget; 2015 Oct; 6(32):33623-35. PubMed ID: 26378038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
    Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.
    Xiao K; Li YP; Wang C; Ahmad S; Vu M; Kuma K; Cheng YQ; Lam KS
    Biomaterials; 2015 Oct; 67():183-93. PubMed ID: 26218744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
    Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
    ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
    Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.
    Wu D; Yan Y; Wei T; Ye Z; Xiao Y; Pan Y; Orme JJ; Wang D; Wang L; Ren S; Huang H
    Cell Rep; 2021 Feb; 34(7):108744. PubMed ID: 33596421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
    Wei M; Xie M; Zhang Z; Wei Y; Zhang J; Pan H; Li B; Wang J; Song Y; Chong C; Zhao R; Wang J; Yu L; Yang G; Yang C
    Eur J Med Chem; 2020 Nov; 206():112677. PubMed ID: 32823005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.
    Vesci L; Bernasconi E; Milazzo FM; De Santis R; Gaudio E; Kwee I; Rinaldi A; Pace S; Carollo V; Giannini G; Bertoni F
    Oncotarget; 2015 Mar; 6(8):5735-48. PubMed ID: 25671299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression.
    Hu Z; Wei F; Su Y; Wang Y; Shen Y; Fang Y; Ding J; Chen Y
    Signal Transduct Target Ther; 2023 Jan; 8(1):11. PubMed ID: 36604412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.
    Clements ME; Holtslander L; Edwards C; Todd V; Dooyema SDR; Bullock K; Bergdorf K; Zahnow CA; Connolly RM; Johnson RW
    Oncogene; 2021 Aug; 40(34):5314-5326. PubMed ID: 34247191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.